393186-07-7

Basic information

• Product Name: Propanoic acid, 2-(3-bromophenoxy)-2-methyl-, 1,1-dimethylethyl ester
• CAS NO: 393186-07-7
• Molecular Formula: C14H19BrO3
• Molecular Weight: 315.207
• Mol File: 393186-07-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-(3-bromophenoxy)-2-methyl-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(3-bromophenoxy)-2-methyl-, 1,1-dimethylethyl ester(393186-07-7)
• EPA Substance Registry System: Propanoic acid, 2-(3-bromophenoxy)-2-methyl-, 1,1-dimethylethyl ester(393186-07-7)

Safety Data

• Hazardous Substances Data: 393186-07-7(Hazardous Substances Data)

Upstream product

• 591-20-8 3-Bromophenol 
• 23877-12-5 tert-butyl bromoisobutyrate 
• 91687-71-7 2-(3-bromophenoxy)-2-methylpropionic acid 
• 115-11-7 isobutene 

Relevant articles and documents

Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

Aberrant activation of Wnt/β-catenin signaling is strongly associated with many diseases including cancer invasion and metastasis. Small-molecule targeting of the central signaling node of this pathway, β-catenin, is a biologically rational approach to abolish hyperactivation of β-catenin signaling but has been demonstrated to be a difficult task. Herein, we report a drug-like small molecule, ZW4864, that binds with β-catenin and selectively disrupts the protein-protein interaction (PPI) between B-cell lymphoma 9 (BCL9) and β-catenin while sparing the β-catenin/E-cadherin PPI. ZW4864 dose-dependently suppresses β-catenin signaling activation, downregulates oncogenic β-catenin target genes, and abrogates invasiveness of β-catenin-dependent cancer cells. More importantly, ZW4864 shows good pharmacokinetic properties and effectively suppresses β-catenin target gene expression in the patient-derived xenograft mouse model. This study offers a selective chemical probe to explore β-catenin-related biology and a drug-like small-molecule β-catenin/BCL9 disruptor for future drug development.

SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

HPPARS ACTIVATORS

Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions a